{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-25-000004","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.121047+00:00","generated_at":"2026-05-28T05:31:13.121672+00:00","sec_items":["2.02","2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Barinthus Bio restructures: cuts 65% workforce, shifts focus to celiac VTP-1000","bullets":["Workforce reduction of ~65%; plans to close UK site, consolidate operations in Germantown, MD.","CFO Gemma Brown (departing April 30, 2025) and COO Graham Griffiths (June 30, 2025) to leave; severance agreements anticipated.","Prioritizes VTP-1000 (celiac disease) with Phase 1 data expected mid-2025; postpones VTP-300 hepatitis B development until partner found.","Preliminary cash, cash equivalents and restricted cash of $112M as of Dec 31, 2024; cash runway extended to start 2027.","Key 2025 milestones: VTP-1000 SAD data mid-2025; HBV003 and IM-PROVE II results in Q2 2025; VTP-850 prostate cancer data Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-25-000004","json":"https://secwatch.observer/filing/0001828185-25-000004.json","markdown":"https://secwatch.observer/filing/0001828185-25-000004.md","text":"https://secwatch.observer/filing/0001828185-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000004/0001828185-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000004/brns-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:31:13.121672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16d1d41337","claim":"Gemma Brown was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..","evidence_excerpt":"the employment of Gemma Brown effective as of April 30, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000004/0001828185-25-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}]},{"claim_id":"8101ebb848","claim":"Graham Griffiths was terminated as Chief Operating Officer at Barinthus Biotherapeutics plc..","evidence_excerpt":"the Company will terminate the employment of Graham Griffiths effective as of June 30, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000004/0001828185-25-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Operating Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}